Cariprazine hydrochloride

"目錄號: HY-14763A

GPCR/G ProteinNeuronal Signaling-

Cariprazine(RGH188)鹽酸鹽有抗精神病活性儒洛,對D3和D2受體有較高親和力精耐,Ki分別為0.09 nM和0.5 nM,對5-HT(1A)受體有一定親和力琅锻。

Dopamine Receptor5-HT Receptor

相關產(chǎn)品

Clozapine N-oxide-Chlorpromazine hydrochloride-Pimavanserin-Brexpiprazole-Lorcaserin Hydrochloride-Haloperidol-Cabergoline-Scopolamine hydrobromide-Harmine-Lu AE58054 Hydrochloride-TG6-10-1-L-DOPA-Perphenazine-Aripiprazole-Dopamine hydrochloride-

生物活性

Description

Cariprazine hydrochloride is a novel antipsychotic drug candidate that exhibits high affinity for theD3(Ki=0.085 nM) andD2(Ki=0.49 nM) receptors, and moderate affinity for the5-HT1Areceptor (Ki=2.6 nM).

IC50& Target

Ki: 0.49 nM (D2 receptor), 0.085 nM (D3 receptor), 2.6 nM (5-HT1A receptor)[1]

In Vitro

Cariprazine stimulates inositol phosphate (IP) formation with a high potency (pEC508.5) with relatively low efficacy (Emax30%)[2]. Cariprazine, a novel candidate antipsychotic, demonstrated approximately 10-fold higher affinity for human D3versus human D2Land human D2Sreceptors (pKi10.07, 9.16, and 9.31, respectively). Cariprazine displays high affinity at human serotonin (5-HT) type 2B receptors (pKi9.24) with pure antagonism. Cariprazine has lower affinity at human and rat hippocampal 5-HT1Areceptors (pKi8.59 and 8.34, respectively) and demonstrates low intrinsic efficacy. Cariprazine displays low affinity at human 5-HT2Areceptors (pKi7.73). Moderate or low affinity for histamine H1and 5-HT2Creceptors (pKi7.63 and 6.87, respectively) suggest Cariprazine's reduced propensity for adverse events related to these receptors[2]. Cariprazine is over sixfold more potent (EC50=1.4 nM) than Aripiprazole (EC50=9.2 nM) in inhibiting isoproterenol-induced cAMP production in HEK-293 cells[4].

In Vivo

Administration of Cariprazine (30 μg/kg) reduces the striatal uptake of both radioligands to the level of nonspecific binding compared with baseline PET measurements. Cariprazine has negligible effect on the time-activity curves in the cerebellum. At doses of 5.0 and 30 μg/kg, Cariprazine causes a dose-dependent dopamine D2/D3receptor occupancy of ~45% and ~80% for both antagonist [11C] raclopride and agonist radioligand [11C]MNPA. Receptor occupancy of dopamine D2/D3receptors calculated using the transient equilibrium and the MRTM2 methods ranged from 5% at the lowest dose (1.0 μg/kg) to 94% at the highest dose (300 μg/kg)[1]. The effects of 5 doses of Cariprazine (ranging from 0.005 to 0.15 mg/kg) are examined on EPM behavior of wild-type mice. Whereas lower doses of Cariprazine (0.005 to 0.02 mg/kg) do not alter the time spent in open arms, the two higher doses (0.08 and 0.15 mg/kg) lead to a significant decline of this measure (ANOVA, (F(5,52)=4.20; p=0.0032)). Moreover, the two higher doses of Cariprazine also lead to a significant decrease in the total number of arm entries (F(5,52)=7.21; p=0.0001)) but this decrease in the total number of arm entries is largely accounted for by a significant decrease in the number of closed arm entries (F(5,52)=11.75; p=0.0001)). The two highest doses of Cariprazine (0.08 and 0.15 mg/kg) have significant effects on locomotor activity, but doses ranging from 0.005 to 0.02 mg/kg do not affect anxiety-like behavior or locomotor activity in the EPM test[3]. A significant (P<0.01) reduction in ouabain-induced hyperactivity is observed after acute i.p. administration of all doses of Cariprazine (mean±SEM: 0.06 mg/kg, 64.2±3.88; 0.25 mg/kg, 72.7±11.67; 0.5 mg/kg, 40.6±5.32; 1 mg/kg, 19.5±8.78) and lithium (40.4±12.78), compared with ouabain injection alone (114.6±14.33). The highest Cariprazine dose produced significant sedation (72% inhibition for Cariprazine 1.0 mg/kg aCSF vs. saline aCSF; P<0.05)[4].

Clinical Trial

NCT01838876

Forest Laboratories-Gedeon Richter Ltd.

Major Depressive Disorder

May 2013

Phase 3

NCT01104792

Forest Laboratories-Gedeon Richter Ltd.

Schizophrenia

April 2010

Phase 3

NCT02670551

Forest Laboratories, LLC, an Allergan Affiliate-Forest Laboratories

Bipolar Disorder-Depression

March 2016

Phase 3

NCT02670538

Forest Laboratories

Bipolar Disorder-Depression

March 2016

Phase 3

NCT01058096

Forest Laboratories-Gedeon Richter Ltd.

Bipolar Disorder-Mania

February 2010

Phase 3

NCT01059539

Forest Laboratories-Gedeon Richter Ltd.

Bipolar I Disorder

January 2010

Phase 3

NCT01715805

Forest Laboratories-Gedeon Richter Ltd.

Major Depressive Disorder

November 2012

Phase 3

NCT01058668

Forest Laboratories-Gedeon Richter Ltd.

Mania-Bipolar I Disorder

February 2010

Phase 3

NCT01396447

Forest Laboratories-Gedeon Richter Ltd.

Depression, Bipolar

July 2011

Phase 2

NCT00839852

Forest Laboratories-Gedeon Richter Ltd.

Schizophrenia

May 2009

Phase 2

NCT01412060

Forest Laboratories-Gedeon Richter Ltd.

Schizophrenia

August 2011

Phase 3

NCT01469377

Forest Laboratories-Gedeon Richter Ltd.

Major Depressive Disorder

December 2011

Phase 2

NCT00852202

Forest Laboratories-Gedeon Richter Ltd.

Bipolar Depression

June 2009

Phase 2

NCT01104779

Forest Laboratories-Gedeon Richter Ltd.

Schizophrenia

April 2010

Phase 3

NCT02165098

Gedeon Richter Plc.

Pharmacokinetic Profile

June 2014

Phase 1

NCT01376076

Forest Laboratories

Schizophrenia

June 2011

Phase 1

NCT01104766

Forest Laboratories-Gedeon Richter Ltd.

Schizophrenia

April 2010

Phase 3

NCT00854100

Forest Laboratories-Gedeon Richter Ltd.

Major Depressive Disorder

June 2009

Phase 2

NCT00488618

Forest Laboratories-Gedeon Richter Ltd.

Bipolar Disorder

June 2007

Phase 2

NCT00862992

Mitsubishi Tanabe Pharma Corporation

Schizophrenia

April 2008

Phase 2

NCT01838876

Forest Laboratories-Gedeon Richter Ltd.

Major Depressive Disorder

May 2013

Phase 3

NCT01104792

Forest Laboratories-Gedeon Richter Ltd.

Schizophrenia

April 2010

Phase 3

NCT02670551

Forest Laboratories, LLC, an Allergan Affiliate-Forest Laboratories

Bipolar Disorder-Depression

March 2016

Phase 3

NCT02670538

Forest Laboratories

Bipolar Disorder-Depression

March 2016

Phase 3

NCT01058096

Forest Laboratories-Gedeon Richter Ltd.

Bipolar Disorder-Mania

February 2010

Phase 3

NCT01059539

Forest Laboratories-Gedeon Richter Ltd.

Bipolar I Disorder

January 2010

Phase 3

NCT01715805

Forest Laboratories-Gedeon Richter Ltd.

Major Depressive Disorder

November 2012

Phase 3

NCT01058668

Forest Laboratories-Gedeon Richter Ltd.

Mania-Bipolar I Disorder

February 2010

Phase 3

NCT01396447

Forest Laboratories-Gedeon Richter Ltd.

Depression, Bipolar

July 2011

Phase 2

NCT00839852

Forest Laboratories-Gedeon Richter Ltd.

Schizophrenia

May 2009

Phase 2

NCT01412060

Forest Laboratories-Gedeon Richter Ltd.

Schizophrenia

August 2011

Phase 3

NCT01469377

Forest Laboratories-Gedeon Richter Ltd.

Major Depressive Disorder

December 2011

Phase 2

NCT00852202

Forest Laboratories-Gedeon Richter Ltd.

Bipolar Depression

June 2009

Phase 2

NCT01104779

Forest Laboratories-Gedeon Richter Ltd.

Schizophrenia

April 2010

Phase 3

NCT02165098

Gedeon Richter Plc.

Pharmacokinetic Profile

June 2014

Phase 1

NCT01376076

Forest Laboratories

Schizophrenia

June 2011

Phase 1

NCT01104766

Forest Laboratories-Gedeon Richter Ltd.

Schizophrenia

April 2010

Phase 3

NCT00854100

Forest Laboratories-Gedeon Richter Ltd.

Major Depressive Disorder

June 2009

Phase 2

NCT00488618

Forest Laboratories-Gedeon Richter Ltd.

Bipolar Disorder

June 2007

Phase 2

NCT00862992

Mitsubishi Tanabe Pharma Corporation

Schizophrenia

April 2008

Phase 2

NCT00404573

Forest Laboratories

Schizophrenia

November 2006

Phase 2

NCT00694707

Forest Laboratories-Gedeon Richter Ltd.

Schizophrenia

June 2008

Phase 2

View MoreCollapse

References

[1].Seneca N, et al. Occupancy of dopamine D2 and D3 and serotonin 5-HT1A receptors by the novel antipsychotic drug candidate, cariprazine (RGH-188), in monkey brain measured using positron emission tomography. Psychopharma

?著作權歸作者所有,轉載或內容合作請聯(lián)系作者
  • 序言:七十年代末卦停,一起剝皮案震驚了整個濱河市,隨后出現(xiàn)的幾起案子恼蓬,更是在濱河造成了極大的恐慌惊完,老刑警劉巖,帶你破解...
    沈念sama閱讀 211,194評論 6 490
  • 序言:濱河連續(xù)發(fā)生了三起死亡事件处硬,死亡現(xiàn)場離奇詭異小槐,居然都是意外死亡,警方通過查閱死者的電腦和手機荷辕,發(fā)現(xiàn)死者居然都...
    沈念sama閱讀 90,058評論 2 385
  • 文/潘曉璐 我一進店門凿跳,熙熙樓的掌柜王于貴愁眉苦臉地迎上來,“玉大人疮方,你說我怎么就攤上這事控嗜。” “怎么了骡显?”我有些...
    開封第一講書人閱讀 156,780評論 0 346
  • 文/不壞的土叔 我叫張陵疆栏,是天一觀的道長曾掂。 經(jīng)常有香客問我,道長壁顶,這世上最難降的妖魔是什么珠洗? 我笑而不...
    開封第一講書人閱讀 56,388評論 1 283
  • 正文 為了忘掉前任,我火速辦了婚禮若专,結果婚禮上险污,老公的妹妹穿的比我還像新娘。我一直安慰自己富岳,他們只是感情好蛔糯,可當我...
    茶點故事閱讀 65,430評論 5 384
  • 文/花漫 我一把揭開白布。 她就那樣靜靜地躺著窖式,像睡著了一般蚁飒。 火紅的嫁衣襯著肌膚如雪。 梳的紋絲不亂的頭發(fā)上萝喘,一...
    開封第一講書人閱讀 49,764評論 1 290
  • 那天淮逻,我揣著相機與錄音,去河邊找鬼阁簸。 笑死爬早,一個胖子當著我的面吹牛,可吹牛的內容都是我干的启妹。 我是一名探鬼主播筛严,決...
    沈念sama閱讀 38,907評論 3 406
  • 文/蒼蘭香墨 我猛地睜開眼,長吁一口氣:“原來是場噩夢啊……” “哼饶米!你這毒婦竟也來了颅围?” 一聲冷哼從身側響起辣卒,我...
    開封第一講書人閱讀 37,679評論 0 266
  • 序言:老撾萬榮一對情侶失蹤禾嫉,失蹤者是張志新(化名)和其女友劉穎涩拙,沒想到半個月后,有當?shù)厝嗽跇淞掷锇l(fā)現(xiàn)了一具尸體丧慈,經(jīng)...
    沈念sama閱讀 44,122評論 1 303
  • 正文 獨居荒郊野嶺守林人離奇死亡析命,尸身上長有42處帶血的膿包…… 初始之章·張勛 以下內容為張勛視角 年9月15日...
    茶點故事閱讀 36,459評論 2 325
  • 正文 我和宋清朗相戀三年,在試婚紗的時候發(fā)現(xiàn)自己被綠了逃默。 大學時的朋友給我發(fā)了我未婚夫和他白月光在一起吃飯的照片鹃愤。...
    茶點故事閱讀 38,605評論 1 340
  • 序言:一個原本活蹦亂跳的男人離奇死亡,死狀恐怖笑旺,靈堂內的尸體忽然破棺而出昼浦,到底是詐尸還是另有隱情,我是刑警寧澤筒主,帶...
    沈念sama閱讀 34,270評論 4 329
  • 正文 年R本政府宣布关噪,位于F島的核電站,受9級特大地震影響乌妙,放射性物質發(fā)生泄漏使兔。R本人自食惡果不足惜,卻給世界環(huán)境...
    茶點故事閱讀 39,867評論 3 312
  • 文/蒙蒙 一藤韵、第九天 我趴在偏房一處隱蔽的房頂上張望虐沥。 院中可真熱鬧,春花似錦泽艘、人聲如沸欲险。這莊子的主人今日做“春日...
    開封第一講書人閱讀 30,734評論 0 21
  • 文/蒼蘭香墨 我抬頭看了看天上的太陽天试。三九已至,卻和暖如春然低,著一層夾襖步出監(jiān)牢的瞬間喜每,已是汗流浹背。 一陣腳步聲響...
    開封第一講書人閱讀 31,961評論 1 265
  • 我被黑心中介騙來泰國打工雳攘, 沒想到剛下飛機就差點兒被人妖公主榨干…… 1. 我叫王不留带兜,地道東北人。 一個月前我還...
    沈念sama閱讀 46,297評論 2 360
  • 正文 我出身青樓吨灭,卻偏偏與公主長得像刚照,于是被迫代替她去往敵國和親。 傳聞我的和親對象是個殘疾皇子喧兄,可洞房花燭夜當晚...
    茶點故事閱讀 43,472評論 2 348

推薦閱讀更多精彩內容

  • "目錄號: HY-14763 GPCR/G ProteinNeuronal Signaling- Caripraz...
    莫小楓閱讀 475評論 0 0
  • "目錄號: HY-14566 Neuronal Signaling- Donepezil(E 2020)是AChE...
    莫小楓閱讀 657評論 0 0
  • "目錄號: HY-15368 GPCR/G ProteinNeuronal Signaling- Lorcaser...
    莫小楓閱讀 566評論 0 0
  • 林寸閱讀 98評論 0 0
  • 文|沒有春 如果.愛 你就不會涩咖,在我最需要你的時候 轉身而去 那時的我,事業(yè)陷入低谷 焦灼于繁莹,堅持還是放棄 企盼的...
    沒有春閱讀 222評論 6 12